SciClone Pharmaceuticals Inc
Shidong Zhang has extensive experience in the pharmaceutical industry. Shidong started their career as a Surgeon at 262 Hospital from 1988 to 1996. Shidong then worked as a Medical Representative at Boehringer Ingelheim from 1997 to 1998. Shidong joined Novartis in 1998 and held various roles including Brand Manager, Medical Advisor, Project Manager, and BU Head Assistant until 2004. From 2005 to 2010, they served as the Marketing Director for Pain/Osteoporosis at Novartis. Shidong then joined Novartis Beijing as the Marketing Director for PC&Specialty from 2010 to 2011. Shidong also held the position of Head of MSL at Novartis Beijing from 2011 to 2012. Shidong then moved to Bayer Healthcare, South Region as the Head of MSL from 2012 to 2014. Shidong is currently working at SciClone Pharmaceuticals as the VP of Marketing & Medical Affairs, a position they have held since 2014.
Shidong Zhang completed their Master's degree in medicine from the Third Military Medical University between 1980 and 1988. From 1996 to 1997, they attended Beijing Language and Culture University to study English. In 2004 to 2006, Shidong Zhang pursued an Executive Master of Business Administration (EMBA) degree from China Europe International Business School (CEIBS).
This person is not in any offices
SciClone Pharmaceuticals Inc
SciClone Pharmaceuticals, Inc. is a pharmaceutical company. The Company's product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company's business is focused primarily in the People's Republic of China. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong. The Company's lead product ZADAXIN (thymalfasin) is approved in over 30 countries, which is used for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV), and certain cancers according to the local regulatory approvals, and for use as an immune system enhancer. In addition to ZADAXIN, SciClone markets seven partnered and in-licensed products in China. The Company sells ZADAXIN in various international markets through its subsidiary, SciClone Pharmaceuticals International Ltd. (SPIL). Its development portfolio includes Angiomax, Loramyc, Neucardin, VIBATIV and Cleviprex.